Acadia Pharmaceuticals Inc. and Allergan Inc. will continue to collaborate on drug discovery and development of new therapeutics for glaucoma and other ophthalmic indications through March 2013 under the terms of an extension that adds a year to the research term originally established in March 2003.
The glaucomas continue to intrigue us with unsolved mysteries. Paul Palmberg, MD, PhD, enumerated several examples during Glaucoma Subspecialty Day at the annual meeting of the American Academy of Ophthalmology. He challenged investigators to find the answers.
The American Academy of Ophthalmology has issued recommendations to help ophthalmologists optimize the benefits and minimize the risks of genetic testing.
The Albert and Margaret Alkek Foundation has honored Danny B. Jones, MD, chairman of ophthalmology at the Baylor College of Medicine, with a lead gift of $500,000 to establish an endowed chair in his name.
A new research paradigm may move glaucoma out of the realm of eye disease and characterize it as a neurologic disorder that causes nerve cells in the brain to degenerate and die, similar to what occurs in Parkinson's and Alzheimer's diseases.
Scientists from the Schepens Eye Research Institute have discovered how a bacterial pathogen can break down the protective molecules on mucous membrane to enter and infect a part of the body.
SARcode Bioscience Inc. has completed patient enrollment in its first pivotal phase III clinical study (OPUS-1) of SAR 1118 ophthalmic solution for dry eye disease.
Bausch + Lomb has acquired the rights to a novel platform technology for treating posterior segment diseases of the eye.
A new supplement (Diabetic Vision Formula, EyeScience Labs) is designed to help protect against potential vision problems associated with diabetic retinopathy.
Bayer HealthCare plans to launch aflibercept injection (Eylea, also known as VEGF Trap-Eye) for the treatment of patients with neovascular age-related macular degeneration in Australia in the second half of this year after having received approval from the Australian Therapeutic Goods Administration.
Wavefront-guided ablation using either LASIK or PRK is a safe and effective therapeutic option for improving visual problems in patients with a history of radial keratotomy, according to Mounir A. Khalifa, MD.
A single bottle of anti-inflammatory eye drops cannot be labeled for use in two eyes postoperatively, voted the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee at a Feb. 27 meeting.
An intravitreal insert with sustained-release fluocinolone acetonide (Iluvien, Alimera Sciences) is approvable for use as a treatment for diabetic macular edema in Europe, according to the outcome of the decentralized procedure for multinational marketing there.
EyeGate Pharma has begun enrolling patients with anterior scleritis into a phase I study evaluating the safety and effectiveness of its lead product, dexamethasone phosphate ophthalmic solution 40 mg/ml (EGP-437), which the company believes has multiple indications for inflammatory ocular indications.
The University of Manitoba has initiated an ophthalmology residency program. The 5-year program, which will be sited at Misericordia Health Centre's Buhler Eye Care Centre, marks the first ophthalmology residency program in the province since 1982.
As part of Workplace Eye Wellness Month, Prevent Blindness America is providing employers with two programs to help protect their employees' vision: the Eye2Eye initiative and the Healthy Eyes Educational Series.
Nidek has granted Marco Ophthalmic exclusive rights to sell Nidek's newest fundus camera (AFC Non-mydriatic Retinal Camera) to the optometry market.
OptiMedica Corp. has launched its proprietary femtosecond laser platform (Catalys Precision Laser System) in the United States, with the first patient cases performed at the Mann Eye Institute and Laser Center in Houston.
Based on our experience over the years, we believe the rules of investing and planning for retirement that one can feel confident in have changed forever.
Cataract surgery can be beneficial in patients with low vision.
Nationally publicized outbreaks of Streptococcus endophthalmitis following intravitreal injection of bevacizumab resulted in a close look at the procedures used to prepare the drug.
Male gender and younger age were identified as risk factors for IOP elevation after dexamethasone implant treatment in retinal vein occlusion in a recent subset analysis, but the elevated IOP did not seem to affect improvement in visual acuity or anatomic outcomes evaluated with optical coherence tomography.
Infectious uveitis is usually diagnosed based on the clinical findings with consideration of the duration and progression of the disorder, the appearance of the inflammation, and the extent of the retinal involvement.
The HORIZON Retinal Vein Occlusion Study, an extension study of the BRAVO Study, found that long-term multiple intravitreal injections of ranibizumab were well-tolerated by patients with branch retinal vein occlusion and central retinal vein occlusion.
For corneal researchers, gaining access to any sizable amount of high quality tissue has long been a challenge.
Six years after OSI Pharmaceuticals Inc. bought Eyetech Pharmaceuticals Inc. for $650 million on the promise of its treatment for wet age-related macular degeneration, Valeant Pharmaceuticals International Inc. has announced it will acquire Eyetech for $22 million.
Ophthalmologists using a proprietary confocal scanning laser ophthalmoscope with a fundus autofluorescence module can now quantify and track progression of geographic atrophy over time, thanks to the release of new software.
Results from an integrated analysis of data from 12 months of follow-up in the two similarly designed prospective, randomized studies comparing aflibercept and ranibizumab indicate that intravitreal injection of aflibercept every 2 months is safe, predictably effective therapy for neovascular age-related macular degeneration and comparable to monthly ranibizumab 0.5 mg.
The results of the direct comparison of ranibizumab and bevacizumab after 1 year of treatment showed that the two drugs adminisred according to monthly and as-needed protocols produced significant decreases in retinal fluid with small amounts of residual fluid in patients with AMD.
The use of laser to treat diabetic macular edema is often the topic of debate.
